Drug Use Investigation of Zevalin.
Latest Information Update: 10 Oct 2021
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms ZEVALIN-DUI
- Sponsors Bayer; Spectrum Pharmaceuticals
- 30 Sep 2021 Status changed from recruiting to completed.
- 09 Nov 2011 Additional trial acronym ZEVALIN-DUI identified as reported by ClinicalTrials.gov.
- 10 Oct 2011 New trial record